In the fight against COVID-19, two FDA-approved mRNA vaccines were developed by Pfizer/BioNTech (BNT162b2 ... fellow at the Merkin Institute at the California Institute of Technology, wanted to combat ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

The rest is history – Pfizer stepped in and licensed the technology, choosing the most promising of four potential mRNA vaccines from BioNTech. Both Moderna and Pfizer’s shots aced the quickly ...

Penn will receive $467 million under a settlement with German drug manufacturer BioNTech, which partnered with Pfizer to develop a COVID vaccine that relied on mRNA technology developed at the ...

BioNTech SE is advancing its oncology ... with investigational combination therapies in two pan-tumor technology pillars: our mRNA-based cancer immunotherapies for the early, adjuvant setting ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

BioNTech (BNTX) is presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and ...

Penn sued BioNTech in August alleging the university was owed more in royalty payments for the use of the university's patented technology in ... expansion of Penn mRNA advances into animals ...

“We aim to develop BioNTech into a global immunotherapy powerhouse ... of solid tumors with investigational combination therapies in two pan-tumor technology pillars: our mRNA-based cancer ...

German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...